There is an ongoing federal response to the 2019 Novel Coronavirus outbreak. Information will be updated as it becomes available. You can learn more by visiting the CDC’s Coronavirus Disease 2019 (COVID-19) page.
2019 Novel Coronavirus
Medical Countermeasure Partnership Opportunities
BARDA is continuing to work with its stakeholders to identify promising medical countermeasures and technologies to combat the 2019 novel coronavirus (SARS-COV-2). Now, there are three ways your company or organization can contact or partner with BARDA to fight the ongoing novel coronavirus outbreak.
2019 Novel Coronavirus Medical Countermeasure Partnership Opportunities
BARDA is continuing to work with its partners to identify promising medical countermeasures and technologies to combat the 2019 novel coronavirus (SARS-COV-2). Now, there are three ways your company or organization can partner with BARDA to fight the ongoing novel coronavirus outbreak.
BARDA BAA: COVID-19 Areas of Interest
BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003). Specifically, BARDA is pursuing the following products or technologies:
- Diagnostic assays
- Vaccines for novel coronavirus
- Therapeutics for novel coronavirus
- Immunomodulators or therapeutics targeting lung repair
- Pre-exposure and post-exposure prophylaxis for novel coronavirus exposure
- Respiratory protective devices
- Advanced Manufacturing Technologies
To learn more, including targets for product maturity under this announcement, see the newly revised BARDA Broad Agency Announcement.
Novel Coronavirus EZ-BAA
To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) to support a number of new medical countermeasures to fight the COVID-19 outbreak. EZ-BAA submissions are reviewed quickly and require a simple abstract submission; awards are capped at $749,000.Under the EZ-BAA, BARDA is looking for:
- Diagnostic assays
- COVID-19 vaccine
- Advanced manufacturing technologies
To learn more, see the Novel Coronavirus EZ-BAA.
2019 Novel Coronavirus Federal Market Research Initiative
If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners! The federal government established a single point of entry for product developers to submit their research on 2019 novel coronavirus medical countermeasures. Submit a brief description and supporting materials through our Market Research Initiative.
Note that funding is not available through a market research submission alone, and you cannot meet with the USG if you have a pending BAA or EZ-BAA submission on the same topic as your meeting.